Cargando…

Correction to: Novel and emerging therapies for B cell lymphoma

Detalles Bibliográficos
Autores principales:	Ayyappan, Sabarish, Maddocks, Kimi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7888163/ https://www.ncbi.nlm.nih.gov/pubmed/33593346 http://dx.doi.org/10.1186/s13045-020-01022-w

Ejemplares similares

Novel and emerging therapies for B cell lymphoma
por: Ayyappan, Sabarish, et al.
Publicado: (2019)

Correction to: Emerging roles of Myc in stem cell biology and novel tumor therapies
por: Yoshida, Go J.
Publicado: (2018)

Correction to ‘Thermodynamic and structural characterization of an EBV infected B-cell lymphoma transcriptome’
Publicado: (2023)

Correction: Suppression of CD300A inhibits the growth of diffuse large B-cell lymphoma
por: Jiang, Lei, et al.
Publicado: (2017)

Correction: van Bruggen et al. Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma. Cancers 2020, 12, 3837
por: van Bruggen, Jaco A. C., et al.
Publicado: (2021)

Correction to: Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy
por: Wang, Chunmeng, et al.
Publicado: (2021)

Correction to: Secondary B-cell lymphoma associated with the Epstein-Barr virus in chronic lymphocytic leukemia patients
por: Morscio, Julie, et al.
Publicado: (2018)

Correction: Regression of primary cardiac angiosarcoma and metastatic nodules following propranolol as a single agent treatment
por: Galván, Dana C., et al.
Publicado: (2019)

Correction to: Cavity-based lymphomas: challenges and novel concepts. A report of the 2022 EA4HP/SH lymphoma workshop
por: Di Napoli, Arianna, et al.
Publicado: (2023)

Correction to: Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy
por: Sjöholm, Therese, et al.
Publicado: (2023)

Correction: Interferon-γ Promotes Inflammation and Development of T-Cell Lymphoma in HTLV-1 bZIP Factor Transgenic Mice
por: Mitagami, Yu, et al.
Publicado: (2015)

Correction to: Chronic lymphocytic leukaemia/small lymphocytic lymphoma and mantle cell lymphoma: from early lesions to transformation
por: Sander, Birgitta, et al.
Publicado: (2023)

Correction to: Quality of life of survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: a LYSA study
por: Paunescu, Alexandra‑Cristina, et al.
Publicado: (2021)

Correction: Kim et al. Cell Surface GRP94 as a Novel Emerging Therapeutic Target for Monoclonal Antibody Cancer Therapy. Cells 2021, 10, 670
por: Kim, Ji Woong, et al.
Publicado: (2021)

Correction: Murid Gammaherpesvirus Latency-Associated Protein M2 Promotes the Formation of Conjugates between Transformed B Lymphoma Cells and T Helper Cells
por: Fontinha, Diana, et al.
Publicado: (2015)

Publisher Correction: HMGA1-pseudogene7 transgenic mice develop B cell lymphomas
por: De Martino, Marco, et al.
Publicado: (2021)

Correction: Ectopic Expression of Homeobox Gene NKX2-1 in Diffuse Large B-Cell Lymphoma Is Mediated by Aberrant Chromatin Modifications
por: Nagel, Stefan, et al.
Publicado: (2013)

Correction: Panjideh et al. Improved Therapy of B-Cell Non-Hodgkin Lymphoma by Obinutuzumab-Dianthin Conjugates in Combination with the Endosomal Escape Enhancer SO1861. Toxins 2022, 14, 478
por: Panjideh, Hossein, et al.
Publicado: (2022)

Correction: The enhanced expression of the matrix metalloproteinase 9 in nasal NK/T-cell lymphoma
por: Sakata, Koh-ichi, et al.
Publicado: (2008)

Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial
por: Houot, Roch, et al.
Publicado: (2023)

A Rare Case of Midostaurin-Associated Sweet's Syndrome
por: Yasin, Hesham, et al.
Publicado: (2022)

Correction: Emerging NK cell therapies for cancer and the promise of next generation engineering of iPSC-derived NK cells
Publicado: (2022)

Author Correction: Comprehensive analysis of the expression and signifcance of CXCLs in human difuse large B-cell lymphoma
por: Zhou, Xiaonan, et al.
Publicado: (2022)

Correction: Nanoencapsulated rituximab mediates superior cellular immunity against metastatic B-cell lymphoma in a complement competent humanized mouse model
Publicado: (2021)

Correction: Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion
por: Huang, Xiaoyuan, et al.
Publicado: (2021)

Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
por: Kroschinsky, Frank, et al.
Publicado: (2020)

Correction to: Patients with B-cell lymphoma receiving anti-CD20 monoclonal antibody-containing chemotherapies and seroreactive patterns in response to COVID-19 vaccination
por: Inaba, Tohru, et al.
Publicado: (2022)

Correction: Harnessing Soluble NK Cell Killer Receptors for the Generation of Novel Cancer Immune Therapy
por: Arnon, Tal I., et al.
Publicado: (2008)

Correction: Harnessing Soluble NK Cell Killer Receptors for the Generation of Novel Cancer Immune Therapy
por: Arnon, Tal I., et al.
Publicado: (2015)

Management of patients with non-Hodgkin’s lymphoma: focus on adoptive T-cell therapy
por: Perna, Serena Kimi, et al.
Publicado: (2015)

Correction to: The diagnosis and treatment of primary vitreoretinal lymphoma: a review
por: Pulido, Jose S., et al.
Publicado: (2018)

Correction to: Risk of lymphoma subtypes by occupational exposure in southern Italy
por: Ferri, Giovanni Maria, et al.
Publicado: (2020)

Correction to: Treatment Sequencing for Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer
por: Kauffmann-Guerrero, Diego, et al.
Publicado: (2021)

Correction: Comparative oncology DNA sequencing of canine T cell lymphoma via human hotspot panel
por: McDonald, J. Tyson, et al.
Publicado: (2018)

Correction: MYC Expression in Concert with BCL2 and BCL6 Expression Predicts Outcome in Chinese Patients with Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Publicado: (2014)

Correction: MYC Expression in Concert With BCL2 and BCL6 Expression Predicts Outcome in Chinese Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
por: Yan, Li-Xu, et al.
Publicado: (2018)

Correction to: Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma
por: Ogasawara, Ken, et al.
Publicado: (2021)

Correction: MYC/BCL2/BCL6 triple hit and TP53 deletion in a case of high-grade B cell lymphoma receiving CAR T cell immunotherapy
Publicado: (2022)

Novel Therapies for Aggressive B-Cell Lymphoma
por: Foon, Kenneth A., et al.
Publicado: (2012)

Correction: Effect of Immune Reconstitution on the Incidence of HIV-Related Hodgkin Lymphoma
por: Kowalkowski, Marc A., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_bojrdhpaar462dhsgjccml5ofs